Viral Gastroenteritis (Rotavirus)

Significance

Reoviridae, dsRNA. GLOBALLY #1 cause severe dehydrating childhood diarrhea. Pre-vaccine: majority of childhood diarrheal hospitalizations, major under-5 mortality contributor.

Virology

Segmented dsRNA (11 segments) — enables REASSORTMENT (co-infection 2 strains → novel hybrid), same mechanism as General Virus Properties topic. “Wheel-like” EM appearance (double-shelled capsid, radiating spokes) = name origin (“rota”=wheel). Classification: VP7 (G-type) + VP4 (P-type) — analogous to flu H/N. Limited G/P combos = most global disease → makes genotype-targeted vaccine feasible.

Pathogenesis

Feco-oral. HIGHLY environmentally stable, resists many disinfectants (infection control challenge, wards/daycare). Low infective dose. Infects/destroys mature absorptive enterocytes at villus tips → villous atrophy → MALABSORPTIVE component (undigested carbs → osmotic water draw) + SECRETORY component (NSP4 protein = viral enterotoxin). DUAL mechanism (malabsorptive+secretory) — contrast cholera (pure secretory) or EPEC (pure structural damage).

Clinical Manifestations

Incubation 1-3d. Vomiting+fever → watery non-bloody diarrhea, 3-8 days. Vomiting-then-diarrhea sequence + high fluid loss relative to small body size = disproportionately DANGEROUS in infants (rapid dehydration even from “mild” illness). Most infected by age 3-5. Reinfection POSSIBLE but MILDER (partial non-sterilizing immunity) — contrast HAV’s lifelong sterilizing immunity.

Laboratory Diagnosis

ELISA/rapid antigen (ICT) — VP6 group antigen, stool. STANDARD method, fast/cheap/sensitive. EM: visualizes wheel-shaped virion, historical/research use now. RT-PCR: highest sensitivity + genotyping (G/P type), surveillance/vaccine-match monitoring, not routine individual Dx.

Treatment

ENTIRELY SUPPORTIVE. ORS (mild-mod dehydration), IV fluids (severe) — same logic as Cholera. NO specific antiviral. NO antibiotic role (viral). Zinc supplementation + ORS: genuine evidence base, ↓diarrhea duration/severity, resource-limited settings, standard in many guidelines.

Prevention — Vaccination

Oral live attenuated rotavirus vaccine (monovalent/pentavalent formulations): DRAMATIC public health impact, ↓severe disease/hospitalization/mortality — clear vaccine-preventable-disease success story. India NIS: 6, 10, 14 weeks (see Vaccines topic). Selected states only so far, not uniform nationwide.

SAFETY: small ↑INTUSSUSCEPTION risk, esp. if 1st dose OUTSIDE recommended early-infancy window — why schedule specifies narrow age range, no open-ended catch-up.

The Leading Cause of Severe Childhood Diarrhoea

Rotavirus, a double-stranded RNA virus of the Reoviridae family, is globally the single most important cause of severe, dehydrating diarrhoeal disease in infants and young children — before widespread vaccination, it was responsible for the large majority of childhood diarrhoeal hospitalizations and a substantial share of global under-five mortality, making it, by disease burden, arguably the most clinically significant entry in this entire topic despite causing a “simple” watery diarrhoea rather than anything invasive or exotic.

Virology

Rotavirus carries a segmented, double-stranded RNA genome (11 segments) — the same structural feature covered under General Properties of Viruses that enables reassortment, the mechanism by which co-infection with two different rotavirus strains in one host cell can generate a genetically novel hybrid strain, contributing to the virus’s ongoing genotypic diversity in circulation. The virus’s characteristic wheel-like appearance on electron microscopy (a double-shelled capsid with radiating spokes) is literally where its name comes from (rota, Latin for wheel). Classification is by two outer capsid proteins — VP7 (G-type) and VP4 (P-type) — analogous in logic to influenza’s H/N nomenclature, with a limited number of G/P type combinations accounting for the large majority of circulating human disease globally, which is exactly what makes a genotype-targeted vaccine strategy feasible.

Pathogenesis

Transmission is faeco-oral, and the virus is genuinely highly environmentally stable and resistant to many standard disinfectants (a real infection-control challenge in paediatric wards and daycare settings), with a very low infective dose contributing to its efficient spread. Once ingested, rotavirus infects and destroys mature, absorptive enterocytes at the tips of small-intestinal villi, causing villous atrophy/shortening and a resulting malabsorptive component to the diarrhoea (undigested carbohydrate reaching the colon, drawing water osmotically) on top of a genuine secretory component driven by the viral NSP4 protein, which acts as a viral enterotoxin — a mechanistically distinct, dual (malabsorptive plus secretory) diarrhoeal mechanism, in contrast to cholera’s purely secretory or EPEC’s purely structural-damage pattern covered elsewhere in this section.

Clinical Manifestations

After a short incubation (1–3 days), illness typically begins with vomiting and fever, followed by watery, non-bloody diarrhoea lasting roughly 3–8 days — the vomiting-then-diarrhoea sequence and the sheer volume of fluid loss relative to the child’s small size are what make rotavirus disproportionately dangerous in infants specifically, since dehydration can progress rapidly in a small child even from what would be a mild, self-limited illness in an adult. Most children have been infected at least once by age 3–5, with reinfection possible but typically milder on subsequent exposures, reflecting partial, non-sterilizing immunity building with each exposure — a real point of contrast with the essentially lifelong sterilizing immunity conferred by a single HAV infection.

Laboratory Diagnosis

ELISA or immunochromatographic rapid antigen tests on a stool specimen, detecting rotavirus VP6 group antigen, are the standard, widely available diagnostic method — fast, cheap, and sensitive enough for routine clinical use. Electron microscopy of stool can directly visualize the characteristic wheel-shaped virion, historically important but now used mainly in research/reference settings rather than routine diagnosis. RT-PCR offers the highest sensitivity and enables genotyping (G/P type determination), useful for surveillance and monitoring vaccine strain match over time rather than routine individual patient management.

Treatment

Entirely supportive — oral rehydration solution for mild-moderate dehydration, IV fluids for severe dehydration, following the same fluid-replacement logic covered under Cholera — there is no specific antiviral treatment for rotavirus, and antibiotics have no role whatsoever given the viral, non-bacterial aetiology. Zinc supplementation, alongside ORS, has a genuine evidence base for reducing diarrhoeal duration and severity in children in resource-limited settings specifically, and is recommended as part of standard childhood diarrhoea management in many national guidelines for exactly that population.

Prevention: Vaccination

Oral live attenuated rotavirus vaccines (multiple formulations exist, including monovalent and pentavalent products) have had a genuinely dramatic public-health impact since introduction, substantially reducing severe rotavirus disease, hospitalization, and mortality in countries with high vaccine coverage — one of the clearest vaccine-preventable-disease success stories in recent paediatric infectious disease history. Vaccination is now part of the National Immunization Schedule in India, given at 6, 10, and 14 weeks alongside other scheduled infant vaccines (see Vaccines and Immunoprophylaxis), though — as noted under that topic — rollout has so far been staged through selected states rather than uniformly nationwide. A genuine, actively monitored safety consideration is a small increased risk of intussusception associated with rotavirus vaccination, particularly if the first dose is given outside the recommended early-infancy age window — which is exactly why the vaccine schedule specifies a defined, relatively narrow age range for dosing rather than allowing open-ended catch-up administration.